Turning basic research discoveries into marketable products or technologies is a major challenge, especially in drug development. We conceptualize the necessary exploitation skills to go beyond the ??the use and development of things already known? (Levinthal & March, 1993, 108) by discussing how basic and applied research skills need to interact in order to successfully apply inventions to turn them into innovations. Using data on over 4500 clinical trials in the pharmaceutical industry, we find that the likelihood of success increases, when the investigators leading these trials have a skill set that in terms of quantity and quality balances basic and applied science. Importantly, the positive impact of such "bridging" relies on individuals bridging the basic-applied science divide. Inter-individual splitting of basic and applied skills in teams does not compensate for intra-individual bridging skills. Breadth of experience in terms of disease fields reduces success in exploitation and negatively moderates bridging skills.
Introduction
"Translational gap" is a frequently used term to describe the challenge in turning basic scientific discoveries into innovations. The extent to which scientific achievements have been exploited for practical applications lags far behind expectations, especially in the pharmaceutical industry, which has spurred the interest of academia, industry and government alike in overcoming the translational gap (Sung Ns and et al. 2003; Zerhouni 2007) . Prior research has focused on the translational gap between science discoveries and inventions (e.g, Jaffe and Trajtenberg 1996; McMillan, Narin et al. 2000; Gittelman and Kogut 2003; Lim 2004 ) but research on the gap to exploitation -development and testing stage -is lacking. This "translational gap" is particularly eminent in the pharmaceutical industry, where despite increased efforts and investments into research and development (R&D) and major scientific advances, the output of innovative drugs has been declining dramatically over the past years (Hu, Schultz et al. 2007; Woolf 2008; Pammolli, Magazzini et al. 2011 ).
An important question is, whether a balanced skillset of individuals or teams in terms of basic and applied science ("bridging skills") improves success rates of exploitation projects.
There is an emerging debate in the sociological and economics of science literature on the relationship between basic and applied science. Basic and applied science are, on one hand, said to be in logical and normative conflict (Merton 1973; Gittelman and Kogut 2003) ; on the other hand found to be complementary in certain instances (Stokes 1997) and applications (Fleming and Sorenson 2004) . Many inventions are derived from basic science discoveries (McMillan, Narin et al. 2000) , basic science skills increase the ability to absorb knowledge from beyond firm boundaries (Cohen and Levinthal 1990) as well as support information gathering and problem solving (e.g., (Zucker, Darby et al. 2001) .
If basic science is indeed complementary to applied research, four important follow-up questions emerge in terms of i) whether this applies also for exploitation, when turning inventions into innovations, ii) whether the balance between basic science and applied science skills matter, iii) whether bridging skills interfere with breadth in experience in terms of applications and whether iv) basic and applied skills need to be intra-individually bundled or can be split between scientists in a team.
First, we examine an area of development research that has received more limited scholarly attention in comparison to research that analyzes the importance of basic science for exploration output (i.e., invention). While moving from basic science to inventions is generally seen as an explorative task of learning and creating new knowledge, moving from inventions to marketable products represents exploitation of the already existing knowledge base (Gupta, Smith et al. 2006; Liu 2006) . Why is the "exploitative" setting interesting? The capabilities needed for exploitative research are predicted to differ from explorative research (March 1991) . Baum, Li, and Usher conceptualize exploitation to refer "to learning gained via local search, experiential refinement, and selection and reuse of existing routines" (Baum, Li et al. 2000) . Brenner and Tushman (2002, 679) highlight that "exploitative innovations involve improvements in existing components and build on the existing technological trajectory, whereas exploratory innovation involves as shift to a different technological trajectory" (Benner and Tushman 2002) . While the dominant view in prior literature has stressed that experience in the relevant appliances is the dominant success factor in exploitation (Levinthal and March 1993) , increasingly voices have raised to reconsider the dominance of applied research in favor of a broader base of insight (FitzGerald 2005) . Particularly the term "translational medicine" born by practitioners in the pharmaceutical industry point to the importance of bridging skills in exploitation, though we lack empirical insights. More than in exploration, attributing importance to and applying bridging skills might be particularly challenging in exploitation, where appropriation by exclusive use and commercial rewards are the guiding principles. On the other hand the "translational" aspect also illustrates that basic research embedded in an instutional logic where recognition is the sole property right also is an important input factor. We aim to address what enhances success under such circumstances by quantifying the relative importance of either as the input, meaning where the emphasis is placed between the two institutional logics and their incentive systems.
Second, differentiating between having some knowledge in basic science versus having profound knowledge or being a star basic scientist might matter. Obviously highlyaccomplished scientists are important, for example, in terms of improving the quality of new (joiner) scientists (Agrawal, McHale et al. 2013) , increasing citations when joining a department (Azoulay, Zivin et al. 2011) or providing a quality signal to investors (Zucker and Darby 1998) . However, the stars productivity in translating discoveries into inventions has been questioned. Prior studies report that scientists engaged in highly cited academic research produce less valuable patents (Gittelman and Kogut 2003; Toole and Czarnitzki 2009 ) and show a lower likelihood of patenting (Calderini, Franzoni et al. 2007) . A strong orientation towards academic science might limit its transferability or applicability in a commercial context. This might well apply to exploiting activities where both institutional logics are present.
Third, we combine the concept of bridging the basic and applied research divide with the level of breadth in experience on productivity in innovation research (Boh, Evaristo et al. 2014 ). Breadth could be seen as another form of (horizontally) bridging different fields, which would point to a general capability of recombining knowledge domains, however, it might overstrain the scientists' capacity when combined with (vertical) bridging skills between basic and applied science.
Lastly, with more and more large teams are becoming the dominant form of organizing R&D (Wuchty, Jones et al. 2007; Singh and Fleming 2010) ; the question arises of whether bridging skills need to be "within" an individual capable of such activities or whether basic and applied skills can be distributed among team members. The economics of science literature has highlighted that teams enable to assemble different pieces of knowledge from individuals (Jones 2009; Singh and Fleming 2010; Bercovitz and Feldman 2011; Jones and Weinberg 2011) and allow division of labor between team members (Häussler and Sauermann 2014) . However, we conceptualize bridging skills to rely on single individuals who inhibit both basic and applied research skills, which cannot be substituted by a split of basic and applied skills between team members. We test our hypotheses by using a dataset of more than 4500 clinical trials, which have been conducted between the year 2005 and 2012. During clinical trials, a patented invention is tested in its final setting ("the human") for the first time and in a stepwise process. Clinical trials constitute an excellent setting for this kind of research on translational science, and represent an area of major economic relevance facing major hurdles in terms of costs, trial lengths and high failure rates (DiMasi, Feldman et al. 2010; Pammolli, Magazzini et al. 2011 ). The term "translational medicine" highlights the difficult transition between the basic (preclinical) and the clinical stages in the pharmaceutical R&D process. Academia, industry and government jointly increased initiatives to overcome this gap. In our study, we relate the skillset of the principal investigators (i.e., their publication activity in terms of basic and applied science as well as their experience) to the success (i.e., the successful completion of the trial). While prior literature has mostly interpreted publication activity as basic science, we exploit the heterogeneity of publications in terms of basic and applied science and thus can investigate the concept of basic and applied being distinct or along a continuum.
Our findings highlight the importance of human capital bridging the basic and applied science divide for the translation of inventions to innovations. For individuals, a balance skillset is most optimal for taking advantage of the combination of capabilities and knowledge of either science as well as to cope with the idiosyncrasies of the academic and commercial incentives. Also within teams, such individuals confer superior performance. In general, excellence in basic and applied science is not beneficial. Breadth of experience in terms of various diseases lowers success, and negatively moderates bridging.
Our insights contribute to a growing literature on human capital and the production of innovation (Fleming and Sorenson 2003; Toole and Czarnitzki 2009) . Extending prior literature arguing that the relationship between research and innovation is complex (Gittelman and Kogut 2003), we add that individuals who are skilled in basic and applied science are able to bridge the -so far fairly understood -gap from the invention to testing stage. Even in the exploitation phase, where creativity and the linkage to basic science are proposed to be much less prominent (Rothaermel and Deeds 2004) , bridging scientists with an understanding of both basic and applied science enhance success. However, in correspondence with (Gittelman and Kogut 2003) who find that the ability to produce excellent science is detrimental to innovative success, our findings indicate that the right dose of bridging is important as scientists being too much drawn into the academia are sub-optimal. Hence, there is a problematic disconnect between excellence in basic science and in applied science which can only be overcome by balancing the involvement in the two institutional spheres both in terms of quality and quantity.
By disentangling intra-versus inter-individual bridging in teams, we also contribute to the literature on team science (Wuchty, Jones et al. 2007 ). While prior research has shown that knowledge in various domains can be distributed among team members (Jones 2009), bridging is only superior when it is inhibited within individuals and not split between two or more specialized team members. This finding is novel as it speaks to the limits of specialization.
Conceptual Framework

Basic and Applied Research
Basic research has the goal of increasing the scientific knowledge base, which is generally not appropriable, or "pursuing knowledge for its own sake" as often done in academia (Dasgupta and David 1994) , from which industry can source insights for innovations (Zucker, Darby et al. 2001; Henderson, Jaffe et al. 2005) . Basic research generates a public good, whose appropriation is difficult, which's returns can only be expected in the long run and indirect ways, and thus requires public investments. Still, public investments into academic and basic science ultimately have the raison d'être that they are believed to lead different actors to take such discoveries on and apply them to generate a benefit for society (Gibbons and Johnston 1974; Pavitt 1991) . In contrast, applied science is focusing on specific challenges, whose solutions may represent a product, technology or service that can be commercialized and generate financial rewards.
There is a long-standing debate on the relationship between basic and applied science. One strand of proponents argues in favor of a divide between basic and applied as polar phenomena that are diametrical points on a line or as two opposing ends of a continuum, (Bush 1945; Brandl 1998) . Bush (1945) states that basic and applied research follow different logics and thus excellence in one will inhibit the other. The conflicting logic is attributed to different epistemological communities in which scientists in basic science and commercial applications are embedded (Dasgupta and David 1994) . On the other hand, Stokes in his book titled "Pasteur's Quadrant" argues for a different view. He proposes the existence of a third kind of research that obtains both the goal of valuable insights for application (applied science) as well as increasing the knowledge base (basic science), besides the established purely basic and purely applied research endeavors (Stokes 1997).
Innovation research also suggests that basic science drives much of the innovative performance of firms, industries and nations (Rosenberg 1990; Pavitt 1991; Zucker and Darby 1995; Zucker, Darby et al. 1998) . Various mechanisms have been outlined by which basic science impacts industrial innovation. Many inventions are derived directly from basic science discoveries, which is documented by patents citing scientific publications (McMillan, Narin et al. 2000) . For example in life-sciences, firms that publish and developed sophisticated links to academics achieve greater levels of success (Henderson and Cockburn 1994; Owen-Smith and Powell 2004) . Firms support basic research activities of their scientists in order to stay well connected to the community and thereby understand and be able to absorb knowledge from beyond the firm boundaries (Cohen and Levinthal 1990) . Human capital well skilled in basic research support information gathering and problem solving in firms (Zucker and Darby 1996; Zucker, Darby et al. 2001) . Rosenberg ascribes basic science a mediating role in the translation of discoveries (Rosenberg 1990) . Basic science research capabilities are essential for evaluating the outcome of much applied research and for perceiving its possible implications and can provide valuable guidance to the directions in which there is a high probability of payoffs to more applied research (Rosenberg 1990) . Fleming and Sorenson postulate that for coupled inventions, like in pharmaceuticals, basic science is necessary to understand where a specific configuration of components may achieve the highest benefit or which may be most useful and offer the highest potential (Fleming and Sorenson 2004) . Further, Cockburn and Henderson (1994, 1998) find that rewards of basic and applied research act as complements to increase productivity of scientists when analyzing incentive systems inside pharmaceutical firms.
While prior research has emphasized the importance of both skills in basic as well as in applied science to turn discoveries into inventions, we examine the area of the exploitation stage that has received more limited attention. Specifically in the setting of clinical trials, investigators with skills in basic, bench-side research, and applied research may be better at understanding the potential, in designing experiments and trials to test hypotheses efficiently and combine methodologies to create valuable outcomes. Being active in the basic science paradigm should create incentives for the clinicians to report on such findings as they may be publishable, even though clinicians generally are not incentivized to report or act on such findings (DeMonaco, Ali et al. 2006) . Thus, to successfully address the translational block from basic science to improved health, "an interdisciplinary array of clinical investigators" is essential (Sung Ns and et al. 2003) . Hence, we: H1: Bridging skills, i.e., skills in both basic and applied research, increase success in development projects.
Excellence in basic and applied research
Though, there are compelling reasons for the complementary view of basic and applied research, scientists are still confronted with the conflicting tensions between the basic and the applied research paradigms. Bridging both sciences may represent a challenge that needs a very specific skill set. Being too much drawn in one of the two spheres is lowering the skills to bridge exploitation. Gittelman and Kogut (2003) find that patents of scientists with highly impact publications receive fewer patent citations, but concomitantly find investigators with experience in both to increase innovation outputs. Toole and Czarnitzki (2009) also find that there is a tradeoff between basic research productivity and a firm's patent productivity. They differentiate scientifically oriented human capital from commercial oriented human capital gained by firm bioscientists during their careers in academe before they joined or founded a firm. Their results suggest that depth of scientifically oriented human capital is negatively related to a firm patent productivity but positively to the firm attracting an NIH grant after completion of proofof-concept studies.
Hence, we conceptualize bridging skills not only to have a skillset in basic as well as in applied research but also to carefully balance researchers' embeddedness in these two spheres.
H2a: Bridging skills are most effective for the success of development projects if skills in basic and applied are balanced. (Quantity) Furthermore, the concept of stars has received increasingly attention, though with conflicting empirical results. While some proponents claim that star scientists are much more prolific, produce better innovations and have a large impact on the valuation of firms that they advise or found (Zucker and Darby 1995; Darby, Liu et al. 1999; Zucker, Darby et al. 2001; Agrawal, McHale et al. 2013) , others have voiced concerns of overemphasizing the role of starts. Rothaermel and Hess find that it is not the intellectual human capital of star scientists that increases innovative output of a firm, but that of the non-star scientists and though academic scientists may be high-performer in terms of publications and their impact, such scientists produce less innovations (Calderini, Franzoni et al. 2007 ). Too strong a focus on the academic career and basic science may thus result in inferior translational capabilities due to a different motivational or basic science-driven value focus. Bridging scientists that exhibit excellence in both sciences, accordingly, may decrease the success of their product development efforts as they are drawn too much towards the basic science paradigm.
H2b: Excellence in both applied and basic research tilts the balance towards too much engagement in the academic science community and thus decreases success rates of translational research projects. (Quality)
Breadth of Experience and Bridging
While we follow a vertical concept of bridging between basic and applied research, a horizontal concept of bridging would view experience in different research areas as a capability to linking fields. The latter is more a general capability of recombining knowledge but one, which might interact with our (vertical) concept of bridging skills. Broad set of experience or "breadth" is the diversity of experiences and insights that have been accumulated (Fleming, Mingo et al. 2007 ). Some scholars argue that creativity requires a recombination of knowledge, which is best achieved through individuals with broad insights into different fields (Katila and Ahuja 2002) . Too much focus may lead individuals to be trapped within their thinking and their held beliefs about the matter at hand. Others claim that only specializing in one or few fields enables to contribute at the knowledge frontier (Sternberg and O'Hara 1999) . Jones (2009) propagates the "death of the Renaissance man" as researchers are becoming more and more experts in increasingly narrow knowledge domains as an answer to the increasing "burden of knowledge". Researchers require longer learning periods before making contributions and therefore must specialize.
Further, a strong focus enables experts to search locally to determine what beliefs or rules to break, whereas less depth of experience may lead to conformist behavior in terms of beliefs or rules (Weisberg 1999) . Studying the company 3M, Boh et al. (2014) report that having indepth experience in one field leads to more valuable inventions, while breadth of experience is associated with higher numbers of inventions, but less influential ones. Macher and Boerner (2006) in their study of pharmaceutical Contract Research Organizations find that scope in terms of different technological areas reduces the success rates of exploitation projects when not paired with in-depth knowledge in a specific area. They recommend that firms should prioritize development activities.
Breadth in terms of experience in different fields might be advantageous only if recombination matters and if these benefits exceed the costs of sharing attention to various areas instead of concentrating on one. It is likely challenging to use the experience gained in diverse fields to excel at exploitative research in a specific field. This might even be more severe in projects with translational gaps. Because bridging the gap in a specific field is already highly specific and drawing on a high level of tacit knowledge, it may even be constrained when researchers are, additionally, active in various fields. Rosenberg reasons that much technological knowledge in a field deals with "the specific and the particular" (Rosenberg 1978). Individuals who are expected to master the gap as well as mastering and sorting impressions and experiences gained in very diverse applied fields might be overburdened. In translational areas, more vertical focused problem-solving strategies may be favored compared to horizontally broad field knowledge. Bridging scientists are per definition knowledgeable in basic science which is more general per nature than applied knowledge. Being also broad in terms of the applied research/ development fields does not effectively and efficiently guide the investigators in their endeavor. The level of complexity is already too high in order to cope with sharing attention with various fields and being able to make use of the benefit of bridging. The phenomenon is seen at clinics and research hospitals: while investigators may establish their own laboratories in which to research the molecular biology behind the disease that they try to cure, such physicians have to have gained the accreditation for the specialization through years of training in the disease. Therefore,bridging skills are leveraged if the investigator experience is focused on one or few fields.
H3: Breadth of experience in applied research fields negatively moderates the effect of bridging skills on success in exploitation projects.
2.4.Intra-versus inter-individual Bridging
When analyzing the impact of bridging the basic and applied science divide, the extent to which bridging skills are intra-individually or can be inter-individually split between team members is important. In general, an increasing amount of knowledge production is performed by teams rather than individuals (Wuchty, Jones et al. 2007; Singh and Fleming 2010) . Much of prior studies devote this to the notion that knowledge production involves the recombination of different knowledge domains which can be achieved by division of labor among researchers specializing in different fields and recombining their work in teams (Singh & Fleming, 2010; (Singh and Fleming 2010; Bercovitz and Feldman 2011) . On the other hand, individuals have been shown to be more effective in integrating knowledge diversity than teams (Taylor and Greve 2006) . In contrast to this strand of research, our focus is on bridging between scientific spheres -which often appears vertically. The translational capability is likely to have limits in being articulated and codified within teams but rather to be "sticking" within certain individuals (DeMonaco, Ali et al. 2006) . Polanyi (1958, p. 49) states that "the aim of a skillful performance is achieved by the observance of a set of rules which are not known as such to the person following them" (Polanyi 1958). Problem solving processes and learning that lead to innovation result when different knowledge structures coexist in the same mind, when at least one head can fit most of the relevant pieces of knowledge together (Simon 1985) . We thus expect individuals to be able to bridge the basic to applied science paradigms more effectively than teams in which a part of the team members is focused on basic and the other part on applied research. H4: Intra-Individual bridging mediates the beneficial effect of bridging on the translation of inventions, even within teams, not the inter-individual bridging.
Clinical Research Setting
From Bench to Bedside
We test our hypotheses with a dataset on clinical trials. The development of new medical interventions to improve health and lives of patients is a complex, costly and lengthy process with high failure rates. In fact, this process is associated with substantial costs ( drug is tested on human subjects and thus this form of research differs substantially from other forms of research. It is strictly regulated and requires approval by different authorities, before its initiation and is usually conducted at hospitals and medical centers. Developing a new drug or novel drug combinations to market is a well-defined stepwise process that evolved over decades as the different stakeholders, among them pharmaceutical firms and regulators, defined a process that would ensure safety, while maximizing output of novel therapeutics to achieve commercial goals and benefits for patients.
Principal Investigators of Clinical Trials
Clinical research is conducted at research hospitals and led by principal investigators (PIs) who are either employed by these hospitals, public funded institutions or research centers. A principal investigator is responsible for ensuring that an investigation is conducted according to the signed investigator statement, the investigational plan, and applicable regulations for protecting the rights, safety, and welfare of subjects under the investigator's care as well as for the control of drugs under investigation. The investigator has the close oversight over the "ac- 
Measures Dependent Variable
We follow Danzon et al. (2005) and measure success in a given phase as a binary variable whether the drug, treatment or intervention is advanced to the next phase of testing in the same indication or not (Danzon, Nicholson et al. 2005 
Independent Variables
Basic, applied and bridging PIs
Publications of investigators are categorized into basic, applied or bridging researchers according to their publication record. Our ability to differentiate publications based on the research focus of the journal(s) they publish, whether basic or applied, allows us to control for different functionality of the underlying research result. While our category "basic research"
represents publications which tend to be "general" in nature (Pavitt 1991) and not appropriable (Rosenberg 1990), publications within the "applied" journal category may be either of applied research nature, specific to a certain setting, or even intended to position an innovation in the market place (Polidoro and Theeke 2012).
We use the CHI Journal classification system to categorize the PI's publications (Della Malva, Leten et al. 2013) . CHI categorizes journals into 5 levels ranging from 0 (very applied) to 4 (very basic). We code publications in journals from level 0 to 2 as applied and from level 3 and 4 as basic. The cut off points were selected after we presented a sample of 10 journals to 3 researchers and asked them to attribute them to the basic or applied category. For example, Nature as a very strong molecular and mostly basic science journal is categorized to level 4, as well as Biological Chemistry, whereas the New England Journal of Medicine belongs to category 2, which our experts denote as an applied research journal. Further applied journals are for example Current Opinion in Cardiology or American Surgeon.
Citation rates are considerably higher for level 4 journal publications, with the other levels not deviating much from each other, as seen in the Appendix 2. We use two approaches to code the PIs' scientific orientation, the first highlighting the distinct nature of basic and applied science and the second following a continuum view.
First, we code three binary variables: the variable d_bridging is one, if the PIs have at least one publication in the basic applied and in the applied journal category. The binary variable d_basicpubs_only is 1 if the PIs have only basic research publications and respectively d_appliedpubs_only is 1 for PIs with only applied research publications.
Second, as an alternative coding, we viewed the basic and applied orientation along a continuum. In doing so, we coded the binary variable d_balancebridging as being 1, if the PIs had between 25% and 75% of publications in the basic science journals, 0 otherwise. Hence, whereas a PI with 1 out of 10 publications would be viewed as bridging researcher in terms of d_bridging being 1, the same PI would not be classified as "bridging" in terms of the continuum view (i.e., d_balancebridging is 0). In addition, we compute the fraction of basic science 
Inter-vs intra-individual bridging
While the former defined variables relate to the publications of an individual PI, we also take into account that trials list a team of PIs. For the hypothesis testing on whether bridging between basic and applied research needs to be intra-individually versus inter-individually, i.e., split between members of a team of PIs, we also coded team based variables. We code the binary variable d_basicPIs_only as being 1 for teams with only PIs listed who publish in basic scientific journals. Correspondingly, d_appliedPIs_only is coded 1 for teams with only applied investigators. Further binary variables denote whether they had at least one bridging investigator on a trial (d_mixofPIsinbridging), whether the team only had bridging investigators (d_bridgingPIs_only) or whether bridging is achieved through the team by including basic science investigators and applied science investigator on the team (d_bridgingthroughteam) but without having a bridging PI.
Breadth of experience
We measure the level of breadth of experience by counting the number of different disease fields (according to the ICD chapter, e.g., "cancer") in which the investigator has been listed in the 5 years prior to the focal field. The variable is denoted ln_fielddivexp. Given the skewness of the experience measures, we use the logarithmic form (1+log).
Control Variables
Several variables are included which are known or expected to influence the success and duration of clinical trials and will allow us to isolate the bridging effect on trial success.
We control for the experience of the investigators in the disease of the focal trial. The variable ln_disexp is measured as the logarithmic form (1+log) of the accumulated number of trials all investigators conducted over a time span of five years prior to the trial in the given disease field such as cancer (according to the ICD chapter).
We include the variable no_investigators to measure the number of PIs on a trial as well as the accumulated number of publications in the 5 years prior to the trial of all investigators on a trial (no_pubs).
We also control for institutional differences by including the binary variable d_industry for the type of institution to differentiate from university or non-profit sponsors of the trials.
Since big pharma firms might act differently, we code the variable d_bigpharma being 1, if a sponsor belongs to the top 25 pharmaceutical companies according to their sales in 2012. We control for the experience of the sponsor in clinical trials by sponsor_trialsexp which depicts the number of trials the sponsor is listed on the 5 years prior to the focal trial and by including sponsor_disexp to control for the experience in a given disease 5 years prior. We also include how many trials the drug has been tested in in the same phase priordrugtrials_samephase.
Our notion is that it is likely that if a sponsor has conducted already several trials in the same phase, it is more experiences than if it is the first trial in a specific phase. As already outlined above, trial success and duration might differ in regards to the phase of testing. Hence, we include binary variables for the phase (d_phase_0, d_phase_1, d_phase2, d_phase_12, d_phase23) . The reference class is d_phase_1. As a control for size, the variable enrollment counts the number of patients enrolled. We code the number of different sites which are recruiting for a given trial location_count. We also control whether the site is one of the 10% of most prominent sites in the overall trials database (top10site) and whether the trial is conducted in the USA versus non-USA. Furthermore, prior studies report that success rates differ significantly between disease fields. We use the ICD 10 coding system of the WHO to code binary variables for the most prominent disease fields such as cancer, endocrinedisease, mentaldisease, circulatorydisease, infectiousdisease. All other disease areas are coded as otherdisease. Endocrinedisease is used as the reference group in our econometric models.
Descriptive Statistics
Descriptive statistics of the dependent, independent and control variables are reported in Table 1 . 3 We first show the descriptive statistics for all observations in Column 2 and then separate for trials with a single PI (Column 3) and trials with a team of investigators (Column 4). 51% of our trials are led by a single PI. In the following, we briefly comment for the full sample and for the sake of brevity only mention specifics for the sample split.
Our dependent variable success shows a mean of 43% for the full sample which corresponds with prior findings reporting a success rate of 70% for phase 1 and 30% for phase 2 trials, whereby phase 2 trials account for the majority of trials in our sample ( than individual led trials (18 times). Note that we did not include phase 3 or 4 since they usually do not have a follow on test phase. The largest share of tests is conducted in cancer (43%), followed by infectious diseases (7.9%), endocrines (7.5%), mental (6.5%).
*** Table 1 about here ***
Econometric Model: Instrumental Variable approach for Selection of investigators
Examining the causal implications of PI characteristics on the success of clinical trials requires a methodology that takes potential selection of specific PIs on a trial into account.
There are two potential sources of selection: (1) the sponsor trying to select the best PIs for a critical trial and (2) the PI trying to participate in the most interesting trials or the one with a high probability of success. We consulted prior literature and engaged into in-depth discussions with experts of clinical trials to further our understanding of potential selection. We did this with the intention to comprehensively control for the types of influences in our models.
Azoulay (2004) suggests that the capabilities of the investigators are affecting success in trials when hypothesis generation is important (Azoulay 2004). Such hypothesis generation
and testing is especially important in the early phases of the clinical research up to phase 2.
Trials in phase 3 and later focus on statistically proving the effectiveness of the treatment versus placebo or the then-current standard of care, based on its results in phase 2 trials. In our study we focus on trials in phase 0 up to phase 2/3 and control for the specific phases. Huckman and Zinner (2005, p. 180) argue that the experience of the investigator is believed by sponsors to be a "significant predictor of enrollment" of patients in a clinical trial. We control for the number of enrolled patients (Huckman and Zinner 2008).
Our own interviewees expressed that trials are very disease specific. A PI or team of PIs is preferred with experience in the same disease -but the pool of potential investigators with disease specific experience strongly determines their possibility to select between investigators. From these we followed that our variable disexp depicting PIs experience in a specific disease might be endogenous. In addition, we learned that selection possibility depends on the pool of potential investigators. We build on these insights and employ an instrumental variable approach. We run 2 stage least square models and instrument disease experience by the number of investigators which did run a trial in the same disease the five years prior to a focal trial. Since the increasing number of trials over the years impacts the pool of investigators with disease specific experience, we normalize the number by dividing it through the number of total trials. We believe the number of available investigators in a field to be random and independent of the field and successes of therapeutics in the field. Career choices are made on a long-term view, also in terms of specialization. Attractiveness of therapies and therapeutic areas through scientific advancement or developments in therapeutics, though, cannot be predicted and can change a field of practice dramatically within a few years. The case of metastatic melanoma is a prominent example, in which no therapeutics achieved better survival over supportive care until 2011, when the first treatment from the field of immuno-oncology was approved which showed not only improvement in overall survival, but also >10 year complete responses, which could mean cure of the disease (Maio 2012). This revolutionary development not only changed the face of metastatic melanoma, but also of the immunooncology field and has made it much more attractive. Thus, we argue that the number of investigator in a certain disease area to be independent of the attractiveness of a field and assume that the possibility of selecting a highly experienced investigator is correlated with the number of investigators that are working in the disease. Previous research and our interviews did not reveal that PIs with bridging skills are selected consciously so far. We add also a qualitative aspect to the analysis in Models 5a and b by including a measure for excellence, which is measured as a dummy variable for the investigators that are the top 10% of cited scientists over a 5 year period in either their basic or applied science, or both.
Results
Bridging and Breadth of Experience and the Success
Models 5a and b provide support for our hypothesis 2b that being excellent in both realms is too much and has a negative effect on the success rate of a trial. Being among the most cited individuals in both academic and commercially oriented research may divert the focus or the investigator from the trial, or may place focus on other aspects that will increase his or her competitiveness in both worlds of science. This is in line with the findings of Toole and Czarnitzki (2009) that productivity stems not from the stars, but from the non-star scientists as academic human capital, at least to the extent that we consider these to be the stars within the basic research paradigm. Interestingly, being top in applied is positively related to success but being top in basic is negatively related. Excellence in applied research by itself, though, will actually increase success. The negative effect of excellence for bridging scientists on success may result from a kind of "pull effect" towards academe that tilts the balance shown to be important in previous models, and not on excellence per se, which would need to be further investigated *** Table 2 about here *** Table 3 investigates to what extent breadth of experience in disease fields of the investigators impacts success. We only display the 2sls-models with experience in diseases instru- When we add the bridging variables along with the interactions, we find strong support for H4 claiming that breadth of experience negatively moderates the impact of bridging on success. Models 2 to 4 with breadth in terms of field experience reveal that H4 holds for all types of interactions with bridging and breadth of experience in fields. Hence, if breadth of experience is coupled with bridging we find a negative impact on success. Presumably, the level of complexity in coping with sharing attention horizontally in terms of different fields as well as vertically in terms of basic and applied overstrains the capacity of investigators.
*** Table 3 about here ***
Trials with one investigator versus trials with a team of investigators
In the following, we split our sample into trials with just one investigator versus trials with a team of investigators. Our objective is to provide insights whether and how the mechanism of bridging may differ between individual investigators and teams of investigators.
Trials with one PI and Bridging
In the Appendix 3, we show models for the sample with one investigator. We restrict the table to report the 2sls models with the instrumental variable approach for disease experience (ln_disexp) but for reader's interest re-run Model 1 as a probit. The results with the probit model are quite similar to the 2sls, though sometimes shows larger significance of coefficients. Comparing the 2sls-models of the reduced sample in Appendix 3 to the 2sls-models with the full sample in Table 2 , we find that the results are quite robust.
When we include our measure for breadth of experience in field along with the interactions, we do not find any significant result neither for ln_fielddivexp nor for the interactions.
Hence, breadth of experience seems not to matter for trial success. In terms of brevity we only report but do not show a table with results.
Teams of Investigators and Bridging
Teams of investigators are more likely to horizontally and vertically tap into different areas by combining specialists in either area within one team. The importance of bridging the basic and applied science divide may thus derive from very different configurations of individuals within teams. Table 4 reports the econometric models including only the observations with two or more investigators on the trial. We briefly comment on our "usual" bridging variables but emphasize Model 5 which splits the bridging measures into inter-and intra-individual bridging. However, teams might have advantages in assembling diverse field experience compared to single PIs. Models 6 to 10 include breadth of field experience as well as its interactions with our bridging variables. Breadth of field experience shows a negative significant effect on success trial suggesting that though teams might be able to acquire diverse field knowledge it is not paying off. Furthermore Models 8 to 10 suggest that breadth of experience even negatively moderates the bridging variables. Only Model 10 which splits teams into intra-and inter-individual bridging does not show any significant interaction effects.
Conclusion
We argue in this paper that individuals who possess a balanced set of skills between basic and applied science can bridge the translational gap between inventions and innovations and improve success rates in product development, by themselves or as members of a team. This Essential to the success of bridging is the relative intensity with which both basic and applied science is conducted by the investigator(s) and serves as input, and where the emphasis is placed between the two systems. Our findings suggest that both activities are complementary up to a certain degree. Excellence in both will actually decrease success. The values and reward systems of the highly cited bridging scientists may still lie too much with the scientific community so as to increase their successes at translating research into product development (Gittelman and Kogut 2003) . As is the case for the balance between exploration and exploitation of (Gupta, Smith et al. 2006) , excellence in both basic and applied science causes a tradeoff that inhibits success in exploitation projects, potentially as excellence in either is mutually exclusive.
The interactive effect of bridging and breadth of experience suggests both benefits and costs to the increasing diversity of activities. Penalties exist for who attempts to master both the vertical translational abilities and attempts broadly apply their expertise across fields, supporting findings by Macher and Boehrner (2006) . The more general ability of bridging diverse fields of exploitation, horizontal bridging, showed negative effects in its interaction with vertical, or basic to applied bridging. The costs of sharing attention to various areas instead of concentrating on one are higher than the benefit of recombining knowledge from diverse fields. Probit  IV  IV  IV  IV  IV  IV  IV  IV  IV  IV 
